Drug Combo Proves Powerful Against Lung Cancer Amityville NY

A two-drug combination treatment in Amityville proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Robert S Weiner
(516) 466-6611
1999 Marcus Ave
New Hyde Park, NY
LAURA DONAHUE, MD
(516) 734-8971
450 Lakeville Road
New Hyde Park, NY
DEBRA FERMAN, MD
(516) 609-3010
333 Glen Head Road
Glen Head, NY
Louis J Lester, MD
516-482-8657
28 Martin Ct
Great Neck, NY
Edward Obedia, MR
631-376-4047
1000 Montauk Hwy
West Islip, NY
Yehuda LeBowicz
(718) 470-8930
27005 76th Ave
New Hyde Park, NY
RONALD BASH, MD
(516) 627-1221
1201 Northern Boulevard
Manhasset, NY
KANTI RAI, MD
(718) 470-7135
270
New Hyde Park, NY
Abu Naser Ziauddin Ahmed, MD
180 E Pulaski Rd
Huntington Station, NY
Bruce Ira Saxe, MD
631-222-2020
700 Stewart Ave
Garden City, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Hormone Therapy for Lung Cancer Amityville NY
Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.
- Genetic Clues for Skin Cancer Therapies Amityville NY
- Risks for Childhood Cancer Survivors Amityville NY
- Hormone Therapy for Breast Cancer Amityville NY
- Exercise for Prostate Cancer Amityville NY
- Delayed Prostate Cancer Therapy Amityville NY
- Fungal Infection Treatments Amityville NY
- Side Effect Of Chemotherapy Drugs Amityville NY
- Exercise for Breast Cancer Survival Amityville NY